Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ImmunoGen Inc Initiates Phase I Testing of EGFR-Targeting ADC, IMGN289


Tuesday, 5 Nov 2013 06:30am EST 

ImmunoGen Inc announced the start of clinical testing with its EGFR-targeting ADC, IMGN289. IMGN289, an ADC, is designed to bind to and kill cancer cells that express EGFR, also known as HER1. 

Company Quote

8.25
0.27 +3.38%
27 Mar 2015